FDA Updates: Retina Trials and Regulatory Pathways - Top-Institutions - MDSpire

FDA Updates: Retina Trials and Regulatory Pathways

William M. Boyd, MD, director of the FDA’s Division of Ophthalmology, discussed the agency’s evolving approaches to clinical evidence, trial design, and expedited regulatory pathways at the 2026 Retina World Congress meeting.

  • By

  • Matthew Solan, senior writer

  • Matthew Solan, senior writer

  • Matthew Solan, senior writer

  • May 14, 2026

  • 6 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Rochester
    University of Rochester

    Rochester, NY

    Key Differentiators

    • Ophthalmology

  • #2

    National Neurovision Research Institute
    National Neurovision Research Institute

    Unknown, Unknown

    Key Differentiators

    • Ophthalmology

  • #3

    Washington University School of Medicine
    Washington University School of Medicine

    St. Louis, MO

    Key Differentiators

    • Ophthalmology

  • #4

    National Eye Institute
    National Eye Institute

    Bethesda, MD

    Key Differentiators

    • Ophthalmology

Original Source(s)

FDA Updates: Retina Trials and Regulatory Pathways

  • by Matthew Solan, senior writer, Matthew Solan, senior writer, Matthew Solan, senior writer

  • May 14, 2026

Related Content

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review

High-grade astrocytoma with piloid features: a case report of comprehensive management